Acadian Asset Management’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.75M | Sell |
2,459,954
-13,611
| -0.6% | -$15.2K | 0.01% | 743 |
|
|
2025
Q1 | $1.95M | Buy |
2,473,565
+999,773
| +68% | +$789K | 0.01% | 758 |
|
|
2024
Q4 | $2.43M | Sell |
1,473,792
-128,328
| -8% | -$212K | 0.01% | 719 |
|
|
2024
Q3 | $5.61M | Sell |
1,602,120
-406,742
| -20% | -$1.42M | 0.02% | 476 |
|
|
2024
Q2 | $6.59M | Buy |
2,008,862
+294,738
| +17% | +$966K | 0.02% | 435 |
|
|
2024
Q1 | $12.6M | Sell |
1,714,124
-567,047
| -25% | -$4.16M | 0.04% | 260 |
|
|
2023
Q4 | $8.53M | Buy |
2,281,171
+131,574
| +6% | +$492K | 0.03% | 328 |
|
|
2023
Q3 | $4.56M | Buy |
2,149,597
+1,236,680
| +135% | +$2.62M | 0.02% | 463 |
|
|
2023
Q2 | $4.34M | Buy |
+912,917
| New | +$4.34M | 0.02% | 493 |
|
|
2018
Q2 | – | Sell |
-10,347
| Closed | -$101K | – | 1748 |
|
|
2018
Q1 | $101K | Buy |
+10,347
| New | +$101K | ﹤0.01% | 1211 |
|
|
2016
Q1 | – | Sell |
-1,038
| Closed | -$3K | – | 1400 |
|
|
2015
Q4 | $3K | Buy |
+1,038
| New | +$3K | ﹤0.01% | 1335 |
|
|
2015
Q3 | – | Sell |
-306
| Closed | -$2K | – | 1336 |
|
|
2015
Q2 | $2K | Buy |
+306
| New | +$2K | ﹤0.01% | 1316 |
|